KymaThera is a San Diego biotechnology company developing mutant-selective small-molecule kinase inhibitors for genetically defined diseases such as cancer.
KymaThera develops small-molecule precision therapeutics for genetically defined diseases such as cancer and vascular malformations. A team of experienced drug hunters applies a proprietary structure-based design framework, refined across decades of discovery work that produced multiple approved medicines, to build mutant-selective kinase inhibitors.
The pipeline is led by K-1728, an oral pan-mutant selective PI3Kα inhibitor designed to reach patients whose tumors carry any PI3Kα mutation rather than the subset served by approved PI3Kα medicines. Inhaled ALK5 (TGF-βR1) and mutant-selective JAK2V617F programs extend the same framework to pulmonary fibrosis and myeloproliferative neoplasms, positioning the company across indications where selectivity for the disease-driving mutant is the differentiating axis.
